UniProt O14733
Dual specificity mitogen-activated protein kinase kinase 7 (O14733)
Dual specificity mitogen-activated protein kinase kinase 7 (UniProt O14733), EC 2.7.12.2: 54 experimental structures on GenesisL1, 23 ligands bound, 22 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- O14733
- Protein
- Dual specificity mitogen-activated protein kinase kinase 7
- EC
- 2.7.12.2
- Experimental structures
- 54
- Predicted models
- 0
- Ligands
- 23
- Pockets
- 22 · 9 records with a druggable one
Structures
54 records of O14733 in the MolNFT archive: 54 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 2DYL | Crystal structure of human mitogen-activated protein kinase kinase 7 activated mutant (S287D, T291D) | x-ray diffraction | A | — | — |
| 2DYL | Crystal structure of human mitogen-activated protein kinase kinase 7 activated mutant (S287D, T291D) | x-ray diffraction | A | — | — |
| 3WZU | THE STRUCTURE OF MAP2K7 IN COMPLEX WITH 5Z-7-oxozeaenol | x-ray diffraction | A | — | — |
| 3WZU | The structure of MAP2K7 in complex with 5Z-7-oxozeaenol | x-ray diffraction | A | — | — |
| 4UX9 | Crystal structure of JNK1 bound to a MKK7 docking motif | x-ray diffraction | F, G, H, I | — | — |
| 4UX9 | Crystal structure of JNK1 bound to a MKK7 docking motif | x-ray diffraction | F, G, H, I | — | — |
| 5B2K | A crucial role of Cys218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7 | x-ray diffraction | A | — | — |
| 5B2K | A crucial role of CYS218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7 | x-ray diffraction | A | — | — |
| 5B2L | A crucial role of Cys218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7 | x-ray diffraction | A | — | — |
| 5B2L | A crucial role of CYS218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7 | x-ray diffraction | A | — | — |
| 5B2M | A crucial role of Cys218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7 | x-ray diffraction | A | — | 4 (best 0.66) |
| 5B2M | A crucial role of CYS218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7 | x-ray diffraction | A | — | — |
| 5Y8U | Crystal structure of the C276S mutant of MAP2K7 | x-ray diffraction | A | — | 2 (best 0.64) |
| 5Y8U | Crystal structure of the C276S mutant of MAP2K7 | x-ray diffraction | A | — | — |
| 5Y90 | MAP2K7 mutant -C218S | x-ray diffraction | A | — | — |
| 5Y90 | MAP2K7 mutant -C218S | x-ray diffraction | A | — | — |
| 5Z1D | MAP2K7 C276S mutant-inhibitor | x-ray diffraction | A | 95U | — |
| 5Z1E | MAP2K7 C218S mutant-inhibitor | x-ray diffraction | A | 95U | 3 (best 0.57) |
| 5Z1E | MAP2K7 C218S mutant-inhibitor | x-ray diffraction | A | 95U | — |
| 6IB0 | The structure of MKK7 in complex with the covalent 4-amino- pyrazolopyrimidine 3A | x-ray diffraction | A | H8Z | — |
| 6IB2 | The structure of MKK7 in complex with the covalent 4-amino-pyrazolopyrimidine 4a | x-ray diffraction | A | 862 | — |
| 6IB2 | The structure of MKK7 in complex with the covalent 4-amino- pyrazolopyrimidine 4A | x-ray diffraction | A | 862 | — |
| 6QFL | Structure of the mitogen activated kinase kinase 7 active conformation | x-ray diffraction | A | — | — |
| 6QFR | Structure of the mitogen activated kinase kinase 7 dfg-out conformation | x-ray diffraction | A | — | — |
| 6QFT | Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidin 1B | x-ray diffraction | A | J0B | — |
| 6QG4 | Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidine inhibitor 1H | x-ray diffraction | A | J0E | — |
| 6QG7 | Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidine 1k | x-ray diffraction | A | 6HL | 2 (best 0.74) |
| 6QG7 | Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidine 1K | x-ray diffraction | A | 6HL | — |
| 6QHO | Dual specificity mitogen-activated protein kinase kinase 7 in complex with pyrazolopyrimidine 1A | x-ray diffraction | A | J3H | — |
| 6QHR | Structure of the mitogen activated kinase kinase 7 in complex with pyrazolopyrimidine 1M | x-ray diffraction | A | J3N | — |
| 6YFZ | Crystal structure of MKK7 (MAP2K7), apo form | x-ray diffraction | A | — | 2 (best 0.64) |
| 6YFZ | Crystal structure of MKK7 (MAP2K7), apo form | x-ray diffraction | A | — | — |
| 6YG0 | Crystal structure of S287D,T291D MKK7 (MAP2K7), apo form | x-ray diffraction | A | — | — |
| 6YG1 | Crystal structure of MKK7 (MAP2K7) in an active state, allosterically triggered by the N-terminal… | x-ray diffraction | A, B, C | NA | — |
| 6YG2 | Crystal structure of MKK7 (MAP2K7) in complex with ibrutnib, with covalent and allosteric binding… | x-ray diffraction | A | 1E8, 8E8 | — |
| 6YG2 | Crystal structure of MKK7 (MAP2K7) in complex with ibrutnib, with covalent and allosteric binding… | x-ray diffraction | A | 1E8, 8E8 | — |
| 6YG3 | Crystal structure of MKK7 (MAP2K7) covalently bound with CPT1-70-1 | x-ray diffraction | A | 6HF | — |
| 6YG4 | Crystal structure of MKK7 (MAP2K7) in complex with K00007 | x-ray diffraction | A | SU9 | — |
| 6YG5 | Crystal structure of MKK7 (MAP2K7) in complex with ASC69 | x-ray diffraction | A | IHH | — |
| 6YG6 | Crystal structure of MKK7 (MAP2K7) covalently bound with type-II inhibitor TL10-105 | x-ray diffraction | A, B | OQ8 | — |
| 6YG7 | Crystal structure of MKK7 (MAP2K7) covalently bound with type-II inhibitor SB1-G-23 | x-ray diffraction | A, B | OQ2 | — |
| 6YZ4 | Crystal structure of MKK7 (MAP2K7) with ibrutinib bound at allosteric site | x-ray diffraction | A | 1E8 | — |
| 7CBX | Crystal structure of MAP2K7 complexed with a covalent inhibitor 12 | x-ray diffraction | A | FU6 | — |
| 7OVI | Protein kinase MKK7 in complex with phenethyltriazole-substituted pyrazolopyrimidine | x-ray diffraction | A | 2GI | — |
| 7OVJ | Protein kinase MKK7 in complex with difluoro-phenethyltriazole-substituted pyrazolopyrimidine | x-ray diffraction | A | 24N | 1 (best 0.71) |
| 7OVJ | Protein kinase MKK7 in complex with difluoro-phenethyltriazole- substituted pyrazolopyrimidine | x-ray diffraction | A | 24N | — |
| 7OVK | Protein kinase MKK7 in complex with 5-bromo-2-hydroxyphenyl-substituted pyrazolopyrimidine | x-ray diffraction | A | 2I5 | 3 (best 0.68) |
| 7OVK | Protein kinase MKK7 in complex with 5-bromo-2-hydroxyphenyl- substituted pyrazolopyrimidine | x-ray diffraction | A | 2I5 | — |
| 7OVL | Protein kinase MKK7 in complex with methoxycyclohexyl-substituted indazole | x-ray diffraction | A | 1XZ | 3 (best 0.59) |
| 7OVL | Protein kinase MKK7 in complex with methoxycyclohexyl-substituted indazole | x-ray diffraction | A | 1XZ | — |
| 7OVM | Protein kinase MKK7 in complex with cyclobutyl-substituted indazole | x-ray diffraction | A | 21I | — |
| 7OVN | Protein kinase MKK7 in complex with tolyl-substituted indazole | x-ray diffraction | A | 2I8 | 2 (best 0.69) |
| 7OVN | Protein kinase MKK7 in complex with tolyl-substituted indazole | x-ray diffraction | A | 2I8 | — |
| O14733 | AlphaFold monomer V2.0 prediction for dual specificity mitogen- activated protein kinase kinase 7… | — | — | — |
Ligands
- 1E8 · 1-{(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl}prop-2-en-1-one · in 3 records
- 95U · N-[3-(6-methyl-1H-indazol-3-yl)phenyl]prop-2-enamide · in 3 records
- 1XZ · 3-(2~{H}-indazol-3-yl)-~{N}-[[1-[(1~{R},2~{R})-2-methoxycyclohexyl]-1,2,3-triazol-4-yl]methyl]-5-(propanoylamino)benzamide · in 2 records
- 24N · 1-[(3~{R})-3-[4-azanyl-3-[1-[2,2-bis(fluoranyl)-2-phenyl-ethyl]-1,2,3-triazol-4-yl]pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]propan-1-one · in 2 records
- 2I5 · 1-[(3~{R})-3-[4-azanyl-3-[1-(5-bromanyl-2-oxidanyl-phenyl)-1,2,3-triazol-4-yl]pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]propan-1-one · in 2 records
- 2I8 · 3-(1~{H}-indazol-3-yl)-~{N}-[[1-(2-methylphenyl)-1,2,3-triazol-4-yl]methyl]-5-(propanoylamino)benzamide · in 2 records
- 6HL · (R)-1-(3-(4-amino-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one · in 2 records
- 862 · 1-[(3~{R})-3-[4-azanyl-3-[1-(4-ethanoylphenyl)-1,2,3-triazol-4-yl]pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]propan-1-one · in 2 records
- 8E8 · 1-[(3~{R})-3-[4-azanyl-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]propan-1-one · in 2 records
- 21I · ~{N}-[(1-cyclobutyl-1,2,3-triazol-4-yl)methyl]-3-(1~{H}-indazol-3-yl)-5-(propanoylamino)benzamide · in 1 record
- 2GI · 1-[(3~{R})-3-[4-azanyl-3-[1-(2-phenylethyl)-1,2,3-triazol-4-yl]pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]propan-1-one · in 1 record
- 6HF · N-(4-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide · in 1 record
- FU6 · 3-(1H-indazol-3-yl)-5-(prop-2-enoylamino)-N-prop-2-ynyl-benzamide · in 1 record
- H8Z · 1-[(3~{R})-3-(4-azanyl-3-ethynyl-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl]prop-2-en-1-one · in 1 record
- IHH · [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl) amino]quinazolin-2-yl}amino)phenyl]acetonitrile · in 1 record
- J0B · 1-[(3~{R})-3-(4-azanyl-3-iodanyl-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl]propan-1-one · in 1 record
- J0E · 1-[(3~{R})-3-[4-azanyl-3-(4-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]propan-1-one · in 1 record
- J3H · 1-[(3~{R})-3-(4-azanylpyrazolo[3,4-d]pyrimidin-1-yl) piperidin-1-yl]propan-1-one · in 1 record
- J3N · 1-[(3~{R})-3-[4-azanyl-3-(1~{H}-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]propan-1-one · in 1 record
- NA · Sodium ion · in 1 record
- OQ2 · ~{N}-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[2-[[(3~{R})-1-propanoylpyrrolidin-3-yl]amino]pyrimidin-4-yl]oxy-benzamide · in 1 record
- OQ8 · ~{N}-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[2-[[(3~{S})-1-propanoylpyrrolidin-3-yl]amino]pyrimidin-4-yl]oxy-benzamide · in 1 record
- SU9 · (3Z)-3-(1H-imidazol-5-ylmethylene)-5-methoxy-1H-indol-2(3H)-one · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.